614 McKinley Place N.E.
153 articles with Bio-Techne
Integrated Workflow Combines NanoString's GeoMx DSP High-Plex RNA Assays and Bio-Techne's Highly Sensitive RNAscope Imaging Reagent Portfolio
Bio-Techne Corporation announced that Jim Hippel, Chief Financial Officer will present at the Barclays Global Healthcare Conference on Wednesday, March 13th, 2019, at 9:00 a.m. EST.
The CiteAb Awards celebrate the very best suppliers and individuals in the research sector worldwide.
Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd, China. Liwen Pei, Managing Director of Bio-Techne China, and Ning Zhou, CEO of Lisen, attended the meeting and signing ceremony
Bio-Techne Corporation today reported its financial results for the second quarter ended December 31, 2018.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2018.
ExoDx® Prostate(IntelliScore) (EPI) Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Bio-Techne Corporation today announced the National Comprehensive Cancer Network decision to include EPI as a recommended test in their Clinical Practice Guidelines in Oncology for Prostate Cancer Early Detection.
Bio-Techne today announced the launch of a new customizable cartridge format for their ProteinSimple-branded Ella™ immunoassay platform.
This new system further expands the usability of Maurice's proprietary cartridge and reduces undesirable protein fragmentation during separation.
Bio-Techne announces the launch of their cell and gene therapy portfolio.
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used stem cell compounds, Y-27632 (ROCK inhibitor) and CHIR 99021.
Bio-Techne Corporation today announced that Dave Eansor, President Protein Sciences will present at the Citi 2018 Global Healthcare Conference on Wednesday, December 5, 2018, at 2:10 p.m. EST.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2018.
Bio-Techne Corporation today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2018 Stephens NY Investment Conference on Wednesday, November 7, 2018, at 10:30 a.m. EST.
Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China.
Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu, Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting, September 9-12, 2018, for his contributions to the capillary electrophoresis (CE) field.
Bio-Techne has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing.
Bio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal
Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx® Prostate(IntelliScore) (EPI)
Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses.